Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient

Abstract

Abstract Our rechallenge of cobimetinib in an Erdheim‐Chester Disease (ECD) patient for the rare adverse effect, “dropped head syndrome,” with a previously unexplored cobimetinib regimen was successful. Similar to other experiences with targeted agents in ECD, dosing of cobimetinib may vary to mitigate toxicity without impairing efficacy.

Keywords

• Erdheim‐Chester disease
• hematology
• neurology
• pharmacology